Exchange: NASDAQ·Updated 07:56 PM EST

MNPR News

News
all
press releases
Brokers Issue Forecasts for MNPR FY2026 Earnings
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets raised their FY2026 EPS estimates for shares of Monopar Therapeutics in a report released on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now expects that the compa...
MarketBeat
Brokers Issue Forecasts for MNPR FY2026 Earnings
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets raised their FY2026 EPS estimates for shares of Monopar Therapeutics in a report released on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now expects that the compa...
MarketBeat
More News
Morgan Stanley raised their price target on Monopar Therapeutics from $130.00 to $133.00 and gave the stock an "overweight" rating in a research report on Monday...
MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for Monopar Therapeutics in a report released on Thursday, November 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings...
MarketBeat
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
The open-label trial showed the drug helped the body remove excess copper more effectively and quickly, mainly by increasing copper excretion through stool.
Stocktwits
Monopar Therapeutics (NASDAQ:MNPR) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-monopar-therapeutics-inc-stock...
MarketBeat
Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have earned a consensus recommendation of "Buy" from the thirteen research firms that are presently covering the stock, MarketBeat...
MarketBeat
Wall Street Zen downgraded Monopar Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets increased their Q1 2026 EPS estimates for Monopar Therapeutics in a research report...
MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2026 EPS estimates for Monopar Therapeutics in a report issued on Monday, March 30th. HC...
MarketBeat

Advertisement|Remove ads.